Complement C4 monitoring in the follow-up of chronic hepatitis C treatment
Complement C4 monitoring in the follow-up of chronic hepatitis C treatment
复制标题
DOI：
10.1046/j.1365-2249.2002.01729.x
复制
发表时间：
2002-01-01
影响因子：
4.6
通讯作者：
Colomb, MG
中科院分区：
文献类型：
--
作者：
Dumestre-Perard, C;Ponard, D;Colomb, MG
补体在宿主-病原体关系中的总体作用现在已经很好地理解。然而，它在感染的慢性阶段，如慢性丙型肝炎的参与，是不太好的记录。在这里，结果报告指出，使用特定的C4监测在后续的HCV患者。本研究涉及66例慢性HCV感染患者，单独使用干扰素α 2b或干扰素α 2b +利巴韦林治疗，50例健康成人作为对照。进行补体血液试验，以测量C1 q、C3、C4、甘露聚糖结合凝集素（MBL）、C1 s-C1抑制剂复合物、总（CH 50）和C4（C4 H）溶血活性;将C4比活性作为C4 H/C4蛋白比。还测量了风湿因子（RF）水平。与健康对照组相比，治疗开始前观察到HCV患者的CH 50和特异性C4活性显著降低;其他参数未受影响，未检测到C1 s-C1抑制剂复合物。与此同时，与持续应答者相比，在复发者中观察到特异性C4活性显著降低。这些结果表明，C4比活性的潜在预测功能，以监测对治疗的反应。在6个月时，反应者的特异性C4活性恢复优于无反应者。慢性丙型肝炎的补体激活似乎不涉及经典途径的C1阶段。特异性C4活性和RF滴度之间的负相关性表明RF可能通过凝集素途径参与C4活化。特异性C4监测似乎是慢性丙型肝炎治疗随访的一个有价值的工具，与其他常规调查一起。
The overall role of complement in the host-pathogen relationship is now well understood. However, its involvement at a chronic stage of infection, such as chronic hepatitis C, is less well documented. Here, results are reported which point to the use of specific C4 monitoring in the follow-up of HCV patients. This study concerns 66 patients with chronic HCV infection, treated with interferon alpha 2b alone or with interferon alpha 2b + ribavirin, and 50 healthy adults as controls. Complement blood tests were performed to measure C1q, C3, C4, mannan binding lectin (MBL), C1s-C1 inhibitor complexes, total (CH50) and C4 (C4H) haemolytic activity; specific C4 activity was taken as the C4H/C4 protein ratio. Rheumatoid factor (RF) levels were also measured. A significant reduction in CH50 and specific C4 activity in HCV patients, compared with the healthy controls, was observed before the onset of treatment; the other parameters were not affected and no C1s-C1 inhibitor complexes were detected. At the same time, a significant reduction in specific C4 activity was observed in relapsers compared with sustained responders. These results point to a potential predictive function of C4 specific activity to monitor the response to therapy. Restoration of specific C4 activity at 6 months was better in responders than in non-responders. Complement activation in chronic hepatitis C does not seem to involve the C1 stage of the classical pathway. A negative correlation between specific C4 activity and RF titres suggests a possible involvement of RF in C4 activation, via the lectin pathway. Specific C4 monitoring appears to be a valuable tool for the follow-up of chronic hepatitis C treatment, together with the other conventional investigations.